An observational study in Oropharyngeal Cancer and Human Papillomavirus, sponsored by Johns Hopkins University. Not yet recruiting at 1 site in United States. Open to male participants aged 40 Years to 69 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Johns Hopkins University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 235 studies in Oropharyngeal Neoplasms with a site in United States — 63 open to participants now, 98 under way, 11 of them phase 3. Oropharyngeal Neoplasms · United States.
Among the 235 studies in Oropharyngeal Neoplasms with a site in United States, this one is the 2nd largest by planned enrollment of the 36 observational ones that give a count, is one of 4 that started in 2027, is one of 36 observational ones, reaches primary completion later than 92 of the 97 other live ones, and was the 235th registered.
370 studies on the registry are indexed under Oropharyngeal Neoplasms; 104 are open to participants now.
Browse Oropharyngeal Neoplasms studies →63 of the 235 studies in Oropharyngeal Neoplasms with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
University of Maryland, Baltimore · Sites in United States
Ages 18+
Metaclipse Therapeutics Corporation · Sites in United States
Ages 18+
Corbus Pharmaceuticals Inc. · Sites in United States, Austria, Belgium and 11 more countries
Ages 18+
OHSU Knight Cancer Institute · Sites in United States
Ages 18–89
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 89 Oropharyngeal Neoplasms studies recruiting now, 76 (85%) set no upper age limit and 5 (6%) stop at 75 or younger; none take children under 18; 7 take healthy volunteers.
This study: 40 Years to 69 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
235 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 45 · Phase 2 108 · Phase 3 21 · Phase 4 3
First in 1995; this study’s year is marked. 4 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,500 is above the median of 142 across 75 observational studies indexed under Oropharyngeal Neoplasms.
Median enrollment 42 across the 189 interventional studies, 205 across the 36 observational. Of the 120 that completed or were terminated, 53 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 235 have an industry lead sponsor. The 10 most frequent:
Johns Hopkins University is the lead sponsor of 1,817 studies on the registry; 316 are open to participants now.
Of its 208 completed or terminated interventional studies of FDA-regulated products, 144 (69%) have results posted.
Johns Hopkins University has 2 studies filed under Oropharyngeal Neoplasms — fewer than ten, so there is no comparison to draw.
32 of the studies in Oropharyngeal Neoplasms with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01266044Phase 3M.D. Anderson Cancer CenterControlled Trial Of Acupuncture To Prevent Radiation-Induced Xerostomia | 2026-12-31 |
| NCT05050162Phase 3NRG OncologyComparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer | 2027-02-09 |
| NCT02215265Phase 3Lisette NixonPost-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS) | 2027-10 |
| NCT04609280University of Maryland, BaltimoreSelective Avoidance of Nodal VolumEs at Minimal Risk (GCC 20110) | 2026-12 |
| NCT05312710Aveta Biomics, Inc.Safety and Efficacy of APG-157 in Head and Neck Cancer | 2026-12 |
Add all 32 to your calendar (.ics) → With an account.
Among the 235 studies in Oropharyngeal Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will screen people for biomarkers of Human Papillomavirus (HPV) to form a cohort of people who may be at increased risk of HPV-oropharyngeal cancer (HPV-OPC). The investigators will follow these individuals prospectively to evaluate risk for OPC.
This study will assess HPV16 biomarkers, including serum HPV16 E6 antibodies, plasma and oral HPV16 DNA, and ultrasound, to understand the feasibility and utility of HPV16 biomarker screening to identify those at increased risk of HPV-OPC. This study will screen approximately 2500 people. The focus of the study is to determine whether sequential testing for oral and plasma HPV16 DNA, among those with HPV16 E6 antibodies, improves identification of persistent HPV16 biomarkers indicative of preclinical HPV-OPC and HPV-OPC compared to standalone testing with HPV16 E6 antibodies among people with and without HIV. The study includes community screening, as well as biobank screening with longitudinal follow-up of those who screen positive.
Study Design Overview: This study has an initial screen that includes two populations: screening of biobank samples "biobank group" and screening of healthy members of the community "community group" which can be done via an in-person visit or via remote sample collection. The subset of participants with HPV16 biomarkers detected will be asked to join the longitudinal follow-up. During follow-up, participants will have more samples collected and have a neck ultrasound to look for any precancerous lesions.
The study is led by Dr. Amber D'Souza and Dr. Carole Fakhry (Johns Hopkins). Participants are being enrolled from the MWCCS cohort, from Baltimore, MD, and across the US. If interested, complete the study eligibility form at [link coming] or email hpv@jhu.edu with questions.
The study population will be drawn from multiple sources, including healthy men from the broader U.S. population interested in the study via online self-referral, website outreach, or study outreach, as well as participants from the MACS WIHS Combined Cohort Study (MWCCS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
To be eligible to participate in Part I of this study, an individual must meet the following criteria:
Community and Internet Screen eligibility:
Biorepository Screen eligibility:
Ability to understand and the willingness to sign a written informed consent document
To be eligible to participate in Part II of this study, an individual must meet all of the following criteria:
Exclusion Criteria:
An individual who meets any of the following criteria will be excluded from participation in this study:
History of head and neck cancer
An individual who meets any of the following criteria will be excluded from participation in this part of the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Prospective cohort of adult male participants from two groups: community group (see eligibility form) an biobank group (enrolled from MWCCS cohort). Both groups will undergo initial screening, with eligible participants continuing onto follow-up testing, which may include blood collection, oral rinse collection, anal Pap smear, ultrasound imaging, and surveys.
HPV16 E6 antibodies present or absent in serum sample
To determine whether sequential testing for oral or plasma HPV16 DNA, among those with HPV16 E6 antibodies, improves identification of persistent HPV16 biomarkers indicative of preclinical HPV-OPC and HPV-OPC compared to standalone testing with HPV16 E6 antibodies.
Time frame: Baseline to end of three-year follow-up
Oral HPV16 DNA present or absent
To determine whether sequential testing for oral HPV16 DNA, among those with HPV16 E6 antibodies, improves identification of persistent HPV16 biomarkers indicative of preclinical HPV-OPC and HPV-OPC compared to standalone testing with HPV16 E6 antibodies.
Time frame: Baseline to end of three-year follow-up
Feasibility of community screening
To assess whether primary screening in a community setting of healthy individuals can lead to at least 80% of those with HPV16 E6 antibodies identified agreeing to complete follow-up biomarker collection and ultrasound for secondary screening.
Time frame: Baseline to end of three-year follow-up
Plan to share: Yes — The investigators will utilize a plan for the controlled release, management, and sharing of data. Data will be made available through a study research proposal process.
Start is estimated for Jan 2027; primary completion for Jan 2032, 60 months later.
Of 47 observational studies under Oropharyngeal Neoplasms, half reached primary completion within 110 months of starting (the median), counting those still running; a quarter within 40. This study's planned 60 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.